Cargando…
Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy
Pancreatic carcinosarcoma is a very rare malignancy with a poor prognosis. Because of these characteristics, a treatment strategy for it has not been established yet. The aim of this study was to establish a therapeutic strategy for pancreatic carcinosarcoma. We reviewed data of a 65-year-old female...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Hepato-Biliary-Pancreatic Surgery
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201054/ https://www.ncbi.nlm.nih.gov/pubmed/36775825 http://dx.doi.org/10.14701/ahbps.22-078 |
_version_ | 1785045186534965248 |
---|---|
author | Lee, Mirang Cho, Young Jae Jung, Hye-Sol Yun, Won-Gun Han, Youngmin Kwon, Wooil Jang, Jin-Young |
author_facet | Lee, Mirang Cho, Young Jae Jung, Hye-Sol Yun, Won-Gun Han, Youngmin Kwon, Wooil Jang, Jin-Young |
author_sort | Lee, Mirang |
collection | PubMed |
description | Pancreatic carcinosarcoma is a very rare malignancy with a poor prognosis. Because of these characteristics, a treatment strategy for it has not been established yet. The aim of this study was to establish a therapeutic strategy for pancreatic carcinosarcoma. We reviewed data of a 65-year-old female patient who was diagnosed with pancreatic carcinosarcoma through endoscopic ultrasound-guided fine needle aspiration biopsy before surgery. For literature review, we searched PubMed using terms of “Pancreatic” or “Pancreas” and “carcinosarcoma” or “carcinosarcomatous”. The patient received 11 cycles of neoadjuvant treatment with leucovorin, fluorouracil, irinotecan, oxaliplatin and pembrolizumab because the tumor was borderline resectable. She underwent stereotactic ablative body radiotherapy (SABR) with 35 Gy in 5 fractions, followed by robotic pylorus-preserving pancreaticoduodenectomy. After surgery, the patient received adjuvant chemotherapy in the same regimen as before surgery. She is alive without any recurrence. Among 48 patients within 33 available papers, the median survival time was 15 months. The survival rate of patients who received adjuvant chemotherapy tended to be higher than that of those who did not receive adjuvant chemotherapy, although the difference was not statistically significant (median survival, 47 vs. 15 months; p = 0.485). Three patients who received neoadjuvant chemotherapy had a survival period of 13–23.5 months. Surgery with lymphadenectomy, adjuvant therapy, and neoadjuvant therapy are thought to help improve survival outcomes. Modern treatment approaches for conventional pancreatic ductal adenocarcinoma could be applied to pancreatic carcinosarcoma. |
format | Online Article Text |
id | pubmed-10201054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Association of Hepato-Biliary-Pancreatic Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-102010542023-05-23 Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy Lee, Mirang Cho, Young Jae Jung, Hye-Sol Yun, Won-Gun Han, Youngmin Kwon, Wooil Jang, Jin-Young Ann Hepatobiliary Pancreat Surg Review Article Pancreatic carcinosarcoma is a very rare malignancy with a poor prognosis. Because of these characteristics, a treatment strategy for it has not been established yet. The aim of this study was to establish a therapeutic strategy for pancreatic carcinosarcoma. We reviewed data of a 65-year-old female patient who was diagnosed with pancreatic carcinosarcoma through endoscopic ultrasound-guided fine needle aspiration biopsy before surgery. For literature review, we searched PubMed using terms of “Pancreatic” or “Pancreas” and “carcinosarcoma” or “carcinosarcomatous”. The patient received 11 cycles of neoadjuvant treatment with leucovorin, fluorouracil, irinotecan, oxaliplatin and pembrolizumab because the tumor was borderline resectable. She underwent stereotactic ablative body radiotherapy (SABR) with 35 Gy in 5 fractions, followed by robotic pylorus-preserving pancreaticoduodenectomy. After surgery, the patient received adjuvant chemotherapy in the same regimen as before surgery. She is alive without any recurrence. Among 48 patients within 33 available papers, the median survival time was 15 months. The survival rate of patients who received adjuvant chemotherapy tended to be higher than that of those who did not receive adjuvant chemotherapy, although the difference was not statistically significant (median survival, 47 vs. 15 months; p = 0.485). Three patients who received neoadjuvant chemotherapy had a survival period of 13–23.5 months. Surgery with lymphadenectomy, adjuvant therapy, and neoadjuvant therapy are thought to help improve survival outcomes. Modern treatment approaches for conventional pancreatic ductal adenocarcinoma could be applied to pancreatic carcinosarcoma. The Korean Association of Hepato-Biliary-Pancreatic Surgery 2023-05-31 2023-02-13 /pmc/articles/PMC10201054/ /pubmed/36775825 http://dx.doi.org/10.14701/ahbps.22-078 Text en Copyright © 2023 by The Korean Association of Hepato-Biliary-Pancreatic Surgery https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Lee, Mirang Cho, Young Jae Jung, Hye-Sol Yun, Won-Gun Han, Youngmin Kwon, Wooil Jang, Jin-Young Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy |
title | Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy |
title_full | Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy |
title_fullStr | Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy |
title_full_unstemmed | Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy |
title_short | Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy |
title_sort | collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201054/ https://www.ncbi.nlm.nih.gov/pubmed/36775825 http://dx.doi.org/10.14701/ahbps.22-078 |
work_keys_str_mv | AT leemirang collectivereviewofpancreaticcarcinosarcomaaveryrarepancreaticmalignancy AT choyoungjae collectivereviewofpancreaticcarcinosarcomaaveryrarepancreaticmalignancy AT junghyesol collectivereviewofpancreaticcarcinosarcomaaveryrarepancreaticmalignancy AT yunwongun collectivereviewofpancreaticcarcinosarcomaaveryrarepancreaticmalignancy AT hanyoungmin collectivereviewofpancreaticcarcinosarcomaaveryrarepancreaticmalignancy AT kwonwooil collectivereviewofpancreaticcarcinosarcomaaveryrarepancreaticmalignancy AT jangjinyoung collectivereviewofpancreaticcarcinosarcomaaveryrarepancreaticmalignancy |